40,000 Shares in Danaher Corporation $DHR Purchased by Archon Partners LLC

Archon Partners LLC acquired a new position in shares of Danaher Corporation (NYSE:DHR) during the 4th quarter, HoldingsChannel reports. The firm acquired 40,000 shares of the conglomerate’s stock, valued at approximately $9,157,000.

Several other institutional investors have also modified their holdings of the company. Aristotle Atlantic Partners LLC bought a new position in shares of Danaher during the fourth quarter worth about $229,000. Bamco Inc. NY grew its position in shares of Danaher by 28.3% during the fourth quarter. Bamco Inc. NY now owns 60,709 shares of the conglomerate’s stock worth $13,898,000 after acquiring an additional 13,380 shares during the last quarter. Armistice Capital LLC grew its position in shares of Danaher by 239.2% during the fourth quarter. Armistice Capital LLC now owns 107,035 shares of the conglomerate’s stock worth $24,502,000 after acquiring an additional 75,477 shares during the last quarter. Align Financial LLC bought a new position in shares of Danaher during the fourth quarter worth about $524,000. Finally, Freestone Grove Partners LP bought a new position in shares of Danaher during the fourth quarter worth about $94,495,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR opened at $177.85 on Thursday. The firm’s 50 day moving average is $180.26 and its 200-day moving average is $203.59. The stock has a market capitalization of $125.88 billion, a P/E ratio of 34.40, a P/E/G ratio of 2.31 and a beta of 0.81. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.87 and a quick ratio of 1.52. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, April 20th. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.94 by $0.12. The company had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $6 billion. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The business’s revenue was up 3.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.88 EPS. Equities research analysts anticipate that Danaher Corporation will post 8.45 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be given a $0.40 dividend. The ex-dividend date is Friday, June 26th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.9%. Danaher’s dividend payout ratio (DPR) is 30.95%.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of analyst reports. JPMorgan Chase & Co. reduced their price target on Danaher from $275.00 to $245.00 and set an “overweight” rating for the company in a research report on Wednesday, April 22nd. Wells Fargo & Company dropped their target price on Danaher from $240.00 to $212.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 22nd. HSBC dropped their target price on Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of Danaher in a report on Friday, March 27th. Finally, Rothschild & Co Redburn set a $205.00 target price on Danaher in a report on Friday, April 17th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $233.61.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.